<sup>1</sup>**Guillain-Barré syndrome following Zika virus infection is associated with a diverse**  <sup>2</sup>**spectrum of peripheral nerve reactive antibodies**  3 Alexander J Davies<sup>1</sup>\*, Cinta Lleixà<sup>2</sup>\*, Ana M. Siles<sup>2,3</sup>, Dawn Gourlay<sup>4</sup>, Georgina Berridge<sup>5</sup>, Wanwisa Dejnirattisai<sup>6</sup> , Carolina Ramírez-Santana<sup>7</sup> , Juan-Manuel Anaya<sup>7</sup> <sup>4</sup>, Andrew K. 5 Falconar<sup>8</sup>, Claudia M. Romero-Vivas<sup>8</sup>, Lyda Osorio<sup>9</sup>, Beatriz Parra<sup>9</sup>, Gavin R. Screaton<sup>6</sup>, 6 Juthathip Mongkolsapaya<sup>6,10</sup>, Roman Fischer<sup>5</sup>, Carlos A. Pardo<sup>10</sup>, Susan K. Halstead<sup>4</sup>, Hugh 7 U. Willison<sup>4</sup>, Luis Querol<sup>2,3†</sup>, Simon Rinaldi<sup>1†</sup> 8 1) Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe<br>9 Hospital, Oxford, UK 9 Hospital, Oxford, UK<br>10 2) Neuromuscular Disea 10 2) Neuromuscular Diseases Unit, Neurology Department, Hospital de la Santa Creu i Sant<br>11 Pau. Universitat Autònoma de Barcelona. Barcelona. Spain 11 Pau, Universitat Autònoma de Barcelona, Barcelona, Spain<br>12 3) Centro para la Investigación Biomédica en red en Enferme 12 3) Centro para la Investigación Biomédica en red en Enfermedades Raras – (CIBERER)<br>13 Madrid Spain 13 Madrid, Spain<br>14 4) Institute of Infe 14 4) Institute of Infection, Immunity & Inflammation, University of Glasgow, University Place,<br>15 Glasgow, UK 15 Glasgow, UK<br>16 5) Target Disco 16 5) Target Discovery Institute, NDM Research Building, University of Oxford, Old Road<br>17 Campus Oxford UK 17 Campus, Oxford, UK<br>18 6) Wellcome Centre for 18 6) Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of<br>19 Oxford, Oxford, UK 19 Oxford, Oxford, UK<br>20 7) Center for Autoimm <sup>20</sup>7) Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, 21 Colombia<br>22 8) Departam 22 8) Departamento de Medicina, Universidad del Norte, Barranquilla, Colombia<br>23 9) Grupo de Epidemiología v Salud Poblacional (GESP). School of P 23 9) Grupo de Epidemiología y Salud Poblacional (GESP), School of Public Health,<br>24 Universidad del Valle Cali Colombia 24 **Universidad del Valle, Cali, Colombia**<br>25 10) Dengue Hemorrhagic Fever Resear 25 10) Dengue Hemorrhagic Fever Research Unit, Office for Research and Development,<br>26 Sirirai Hospital, Faculty of Medicine, Mahidol Univeristy, Bangkok, Thailand 26 Siriraj Hospital, Faculty of Medicine, Mahidol Univeristy, Bangkok, Thailand<br>27 11) Department of Neurology, Johns Hopkins University School of Medicine 27 11) Department of Neurology, Johns Hopkins University School of Medicine, Baltimore,<br>28 United States United States 29 \*/† these authors contributed equally to this work. 30 Word count: 4253<br>31 32 <sup>32</sup>**Corresponding authors:** 33 Dr Simon Rinaldi, Nuffield Department of Clinical Neurosciences, University of Oxford, Level<br>34 6. West Wing. John Radcliffe Hospital. Oxford. UK. OX3 9DU. <sup>34</sup>6, West Wing, John Radcliffe Hospital, Oxford, UK. OX3 9DU.

- 35 Email: simon.rinaldi@ndcn.ox.ac.uk<br>36
- 
- 37 37 Dr Luis Querol, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona,<br>38 Mas Casanovas 90, 08041, Barcelona, Spain.
- 38 Mas Casanovas 90, 08041, Barcelona, Spain.<br>39 Email: Iquerol@santpau.cat
- Email: lquerol@santpau.cat

# <sup>40</sup>**ABSTRACT**

# 42 42 **Introduction**<br>43 Recent outbr

43 Recent outbreaks of Zika virus (ZIKV) in South and Central America have highlighted<br>44 significant neurological side effects. Concurrence with the inflammatory neuropathy Guillain-44 significant neurological side effects. Concurrence with the inflammatory neuropathy Guillain-<br>45 Barré syndrome (GBS) is observed in 1:4000 ZIKV cases. Whether the neurological 45 Barré syndrome (GBS) is observed in 1:4000 ZIKV cases. Whether the neurological<br>46 symptoms of ZIKV infection are a consequence of autoimmunity or direct neurotoxicity is 46 symptoms of ZIKV infection are a consequence of autoimmunity or direct neurotoxicity is<br>47 unclear. 47 unclear.<br>48

## 49 <sup>49</sup>**Methods**

50 We employed rat dorsal root ganglion (DRG) neurons, Schwann cells (SCs), and human<br>51 stem cell-derived sensory neurons mvelinated with rat SCs as cellular models to screen for <sup>51</sup>stem cell-derived sensory neurons myelinated with rat SCs as cellular models to screen for 52 IgG and IgM autoantibodies reactive to peripheral nerve in sera of ZIKV patients with and<br>53 vithout GBS. In this study. 52 ZIKV-GBS patients were compared with 134 ZIKV-infected 53 without GBS. In this study, 52 ZIKV-GBS patients were compared with 134 ZIKV-infected<br>54 patients, and 91 non-ZIKV controls. Positive sera were taken forward for target identification 54 patients, and 91 non-ZIKV controls. Positive sera were taken forward for target identification<br>55 by immunoprecipitation and mass spectrometry, and candidate antigens validated by ELISA 55 by immunoprecipitation and mass spectrometry, and candidate antigens validated by ELISA<br>56 and cell-based assavs. Autoantibody reactions against glycolipid antigens were also 56 and cell-based assays. Autoantibody reactions against glycolipid antigens were also<br>57 screened on an arrav. 57 screened on an array.<br>58

# 58 <sup>59</sup>**Results**

60 Overall, IgG antibody reactivity to rat SCs (6.5%) and myelinated co-cultures (9.6%) were<br>61 significantly higher, albeit infrequently, in the ZIKV-GBS group compared to all controls, IgM 61 significantly higher, albeit infrequently, in the ZIKV-GBS group compared to all controls. IgM<br>62 antibody immunoreactivity to DRGs (32.3%) and SCs (19.4%) was more frequently 62 antibody immunoreactivity to DRGs (32.3%) and SCs (19.4%) was more frequently<br>63 observed in the ZIKV-GBS group compared to other controls, while lgM reactivity to co-63 observed in the ZIKV-GBS group compared to other controls, while IgM reactivity to co-<br>64 cultures was as common in ZIKV and non-ZIKV sera. Strong axonal-binding ZIKV-GBS 64 cultures was as common in ZIKV and non-ZIKV sera. Strong axonal-binding ZIKV-GBS<br>65 serum lgG antibodies from one patient were confirmed to react with neurofascin-155 and 65 serum IgG antibodies from one patient were confirmed to react with neurofascin-155 and<br>66 186. Serum from a ZIKV non-GBS patient displaved strong mvelin-binding and anti-lipid 66 186. Serum from a ZIKV non-GBS patient displayed strong myelin-binding and anti-lipid<br>67 antigen reaction characteristics. There was no significant association of ZIKV-GBS with any 67 antigen reaction characteristics. There was no significant association of ZIKV-GBS with any<br>68 anti-glycolipid antibodies. 68 anti-glycolipid antibodies.<br>69

## 70 <sup>70</sup>**Conclusion**

71 Autoantibodies in ZIKV associated GBS patients' sera target heterogeneous peripheral<br>72 nerve antigens suggesting heterogeneity of the humoral immune response despite a 72 nerve antigens suggesting heterogeneity of the humoral immune response despite a<br>73 common prodromal infection. common prodromal infection.

- 74<br>75
- 

## <sup>76</sup>**INTRODUCTION**

77 Zika virus (ZIKV) is a member of the Flavivirus family that is transmitted by Aedes spp.<br>78 mosquito vector species and in humans typically results in asymptomatic or mildly 78 mosquito vector species and in humans typically results in asymptomatic or mildly<br>79 symptomatic infections. An outbreak of ZIKV infections in French Polynesia in 2013 was 79 symptomatic infections. An outbreak of ZIKV infections in French Polynesia in 2013 was<br>80 followed by a spike in the diagnoses of the disabling, acute inflammatory neuropathy 80 followed by a spike in the diagnoses of the disabling, acute inflammatory neuropathy<br>81 Guillain-Barré syndrome (GBS). Early case control studies established one excess GBS 81 Guillain-Barré syndrome (GBS). Early case control studies established one excess GBS<br>82 case for every 4000 people infected with ZIKV.[1] By 2015, the ZIKV pandemic reached 82 case for every 4000 people infected with ZIKV.[1] By 2015, the ZIKV pandemic reached<br>83 South America, where in Colombia the GBS incidence rates were increased by 210-350% 83 South America, where in Colombia the GBS incidence rates were increased by 210-350%<br>84 Compared to the pre-ZIKV period.[2, 3] The overall risk estimates range from 1 to 8 GBS 84 compared to the pre-ZIKV period.[2, 3] The overall risk estimates range from 1 to 8 GBS<br>85 cases per 10.000 ZIKV infections.[4] Recent studies estimate that the total number of ZIKV 85 cases per 10,000 ZIKV infections.[4] Recent studies estimate that the total number of ZIKV<br>86 infections during the 2015-16 outbreak was much higher than originally reported, suggesting 86 infections during the 2015-16 outbreak was much higher than originally reported, suggesting<br>87 previous incidence rates of GBS per infection may have been substantially 87 previous incidence rates of GBS per infection may have been substantially<br>88 underestimated.[5] underestimated.[5]

89 The onset of GBS post-ZIKV infection (ZIKV-GBS) occurred within a median of 6 days after<br>90 a transient febrile illness, though the peak incidence of GBS cases was observed 3 weeks 90 a transient febrile illness, though the peak incidence of GBS cases was observed 3 weeks<br>91 after the peak of ZIKV diagnoses.[1, 2] Whether this represents an infectious, para-infectious 91 after the peak of ZIKV diagnoses.[1, 2] Whether this represents an infectious, para-infectious<br>92 or post-infectious aetiology has been debated. Electrophysiological studies performed on 37 <sup>92</sup>or post-infectious aetiology has been debated. Electrophysiological studies performed on 37 93 ZIKV-GBS patients identified in French Polynesia showed characteristics consistent with the<br>94 acute motor axonal form of GBS (AMAN).[1] However, follow-up studies at 4 months were 94 acute motor axonal form of GBS (AMAN).[1] However, follow-up studies at 4 months were<br>95 more suggestive of distal demvelination.[6] In a Colombian series. 70% of ZIKV-GBS cases 95 more suggestive of distal demyelination.[6] In a Colombian series, 70% of ZIKV-GBS cases<br>96 were classified as acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 96 were classified as acute inflammatory demyelinating polyradiculoneuropathy (AIDP),<br>97 suggestive of immune-mediated iniury.[7] ZIKV has also been linked to a number of central 97 suggestive of immune-mediated injury.[7] ZIKV has also been linked to a number of central<br>98 and peripheral neurological complications, all of which may have an autoimmune 98 and peripheral neurological complications, all of which may have an autoimmune<br>99 mechanism [8]. mechanism [8].

100 A potential role for ZIKV-induced autoimmunity is supported by similarities between the ZIKV<br>101 E protein and human complement component C1q *in silico*, and the presence of C1q <sup>101</sup>E protein and human complement component C1q *in silico*, and the presence of C1q 102 antibodies in the sera of animals infected with the virus.[9] Lynch and colleagues observed<br>103 bigher-titre antibody responses to ZIKV in patients who developed GBS, compared to those 103 higher-titre antibody responses to ZIKV in patients who developed GBS, compared to those<br>104 with uncomplicated infections.[10] More recently, a higher incidence of anti-ganglioside 104 with uncomplicated infections.[10] More recently, a higher incidence of anti-ganglioside<br>105 antibodies was identified in a Brazilian cohort of ZIKV-GBS patients compared to 105 antibodies was identified in a Brazilian cohort of ZIKV-GBS patients compared to<br>106 uncomplicated ZIKV controls [11] suggesting an association between nerve reactive 106 uncomplicated ZIKV controls [11] suggesting an association between nerve reactive<br>107 autoantibodies and the peripheral neurological complications of ZIKV. autoantibodies and the peripheral neurological complications of ZIKV.

108 The peripheral neurology associated with ZIKV infection may also occur via direct viral<br>109 toxicity.[12] ZIKV directly infected peripheral neurons and induced cell death in both mouse toxicity.[12] ZIKV directly infected peripheral neurons and induced cell death in both mouse

- 110 and cell culture models.[13], as well as infecting sensory neurons and Schwann cells (SCs)<br>111 in dorsal root ganglia (DRG) explants from interferon receptor-1 knockout mice leading to
- 111 in dorsal root ganglia (DRG) explants from interferon receptor-1 knockout mice leading to<br>112 myelin fragmentation and later axonal degeneration.[14]
- myelin fragmentation and later axonal degeneration.[14]
- 113 In this study, we sought to address the potential for humoral autoimmunity in ZIKV-GBS by<br>114 screening sera from a large cohort of ZIKV-GBS patients and controls for nerve reactive
- 114 screening sera from a large cohort of ZIKV-GBS patients and controls for nerve reactive<br>115 immunoglobulins using a range of animal and humanised nerve cell cultures and antigen
- 115 immunoglobulins using a range of animal and humanised nerve cell cultures and antigen<br>116 detection methods.
- detection methods.

## <sup>117</sup>**MATERIALS & METHODS**

118 Full details of this section are available in Supplementary Material and Data files.<br>119

## <sup>120</sup>**Patient cohorts and sample acquisition**

121 Serum samples were collected from patients with ZIKV infection both with and without<br>122 neurological complications, as well as from other infectious, healthy and convalescent neurological complications, as well as from other infectious, healthy and convalescent<br>123 controls from the Cucuta. Cali and Barranguilla regions of Colombia, the UK (South Central -123 controls from the Cucuta, Cali and Barranquilla regions of Colombia, the UK (South Central -<br>124 Oxford A approval number 14/SC/0280) and Spain (The Sant Pau Biomedical Research 124 Oxford A approval number 14/SC/0280) and Spain (The Sant Pau Biomedical Research<br>125 Institute approval number IIBSP-AUT-2016-69) (Supplementary Figure 1 and 125 Institute approval number IIBSP-AUT-2016-69) (**Supplementary Figure 1** and<br>126 **Supplementary Table 1**). ZIKV-GBS patients were classified according to previously <sup>126</sup>**Supplementary Table 1**). ZIKV-GBS patients were classified according to previously 127 published electrodiagnostic criteria, [7] with full characterisations previously reported for<br>128 Cucuta [15] and Cali cohorts. [3] Serum samples were aliquoted and stored at -80°C. This 128 Cucuta [15] and Cali cohorts. [3] Serum samples were aliquoted and stored at -80°C. This 129 study was carried out and reported in accordance with the STROBE quidelines.[16] study was carried out and reported in accordance with the STROBE guidelines.[16]

## <sup>130</sup>**Rat DRG neuron and SC culture and immunocytochemistry**

131 Rat DRG neurons and SCs were extracted in accordance with Schedule 1 of the UK Home<br>132 Office Animals (Scientific Procedures) Act 1986, and Animal Ethics' Committee of Hospital 132 Office Animals (Scientific Procedures) Act 1986, and Animal Ethics' Committee of Hospital<br>133 Orte la Santa Creu i Sant Pau. Cells were cultured, and immunocytochemistry was performed 133 de la Santa Creu i Sant Pau. Cells were cultured, and immunocytochemistry was performed<br>134 as previously described.[17] Fluorescence signal intensities were scored on a 0–3 scale by 134 as previously described.[17] Fluorescence signal intensities were scored on a 0–3 scale by<br>135 two independent researchers. two independent researchers.

## <sup>136</sup>**Myelinating co-cultures and immunofluorescence labelling**

137 Myelinating co-cultures were prepared using human induced pluripotent stem cell (hiPSC)-<br>138 derived sensory neurons and neonatal rat SCs as previously described.[18, 19] Sera from 138 derived sensory neurons and neonatal rat SCs as previously described.[18, 19] Sera from<br>139 ZIKV-exposed subiects was diluted to 1:100 and added to live co-cultures for 1h at 37°C. 139 ZIKV-exposed subjects was diluted to 1:100 and added to live co-cultures for 1h at 37°C.<br>140 Fixed cultures were probed with either anti-human IqG. anti-human IqM or anti-human Fixed cultures were probed with either anti-human IgG, anti-human IgM or anti-human

141 complement C3c antibodies. Confocal images were assessed for IgG or IgM reactivity by a<br>142 blinded observer.

blinded observer.

#### <sup>143</sup>**Assessment of serum-induced demyelination**

144 Myelinating co-cultures were incubated for 1h in 'complete' neurobasal media supplemented<br>145 with fluoromvelin red. Serum-free mvelination medium was then supplemented with or 145 with fluoromyelin red. Serum-free myelination medium was then supplemented with or<br>146 without human anti-ZIKV patients' sera at a 1:100 dilution together with 20% normal human 146 without human anti-ZIKV patients' sera at a 1:100 dilution together with 20% normal human<br>147 serum (NHS) as a source of complement and added to the co-cultures. serum (NHS) as a source of complement and added to the co-cultures.

### <sup>148</sup>**Glycoarray**

149 Serum samples were also screened on a glycolipid microarray as previously described.[20]<br>150 For this study, sera were screened against a panel of 16 single glycolipids (GM1, GM2, 150 For this study, sera were screened against a panel of 16 single glycolipids (GM1, GM2,<br>151 phosphatidylserine, GM4, GA1, GD1a, GD1b, GT1a, GT1b, GQ1b, GD3, SGPG, LM1, 151 phosphatidylserine, GM4, GA1, GD1a, GD1b, GT1a, GT1b, GQ1b, GD3, SGPG, LM1,<br>152 cholesterol. GalC and sulphatide) and 120 heteromeric 1:1 (v:v) complexes. printed in 152 cholesterol, GalC and sulphatide) and 120 heteromeric 1:1 (v:v) complexes, printed in<br>153 duplicate. duplicate.

### <sup>154</sup>**Immunoprecipitation and mass spectrometry**

155 Human sera showing moderate or strong reactivity against rat DRG neurons or myelinating<br>156 co-cultures were used for immunoprecipitation (IP) experiments using the same target cell 156 co-cultures were used for immunoprecipitation (IP) experiments using the same target cell<br>157 tvpe. as previously reported.[17] For the mass spectrometry analyses. the IP eluates from 157 type, as previously reported.[17] For the mass spectrometry analyses, the IP eluates from<br>158 mvelinating co-cultures were prepared by chloroform:methanol precipitation and in-solution 158 myelinating co-cultures were prepared by chloroform:methanol precipitation and in-solution<br>159 trypsin digestion. The resultant peptides were then subjected to high resolution C18 reverse-159 trypsin digestion. The resultant peptides were then subjected to high resolution C18 reverse-<br>160 bhase column chromatography and analysed by data-dependant MS/MS on a ThermoFisher 160 phase column chromatography and analysed by data-dependant MS/MS on a ThermoFisher<br>161 Fusion Lumos mass spectrometer. Raw data are available via ProteomeXchange with 161 Fusion Lumos mass spectrometer. Raw data are available via ProteomeXchange with 162 identifier PXD028476. identifier PXD028476.

#### <sup>163</sup>**Protein electrophoresis and Western blot**

164 The lysates from myelinating co-cultures, hiPSC-derived sensory neurons monocultures,<br>165 and primary rat SCs were subjected to electrophoresis in acrylamide gels using MOPS 165 and primary rat SCs were subjected to electrophoresis in acrylamide gels using MOPS<br>166 running buffer under denaturing, non-reducing conditions and then transferred to a 166 running buffer under denaturing, non-reducing conditions and then transferred to a<br>167 nitrocellulose membrane. These blots were probed with using patients' sera at a 1:2500 167 nitrocellulose membrane. These blots were probed with using patients' sera at a 1:2500<br>168 dilution followed by HRP-coniugated Fc-specific anti-human-lgG secondary antibody. The 168 dilution followed by HRP-conjugated Fc-specific anti-human-IgG secondary antibody. The<br>169 bands detected by western blotting were aligned in a parallel gel stained with Pierce Imperial 169 bands detected by western blotting were aligned in a parallel gel stained with Pierce Imperial<br>170 Protein Stain and excised for mass spectrometry. Protein Stain and excised for mass spectrometry.

## <sup>171</sup>**ELISA**

172 Recombinant human nidogen-1, laminins 111, 121, 211, 221, 411, 421, 511 and 521,<br>173 prosaposin and vinculin were coated at 1 ug/ml (100 ul per well) in Maxisorp ELISA plates 173 prosaposin and vinculin were coated at 1 μg/ml (100 μl per well) in Maxisorp ELISA plates<br>174 overnight at 4°C (See **Supplementary Table 2** for details). The ganglioside GM3 ELISA was 174 overnight at 4°C (See **Supplementary Table 2** for details). The ganglioside GM3 ELISA was<br>175 performed as previously described [21]. For the detection of anti-ZIKV antibodies, Maxisorp 175 performed as previously described [21]. For the detection of anti-ZIKV antibodies, Maxisorp<br>176 plates were coated with the anti-flavivirus mouse monoclonal antibody 4G2 and performed 176 plates were coated with the anti-flavivirus mouse monoclonal antibody 4G2 and performed<br>177 as previously described. [22] Bound human lgG antibodies were detected through sequential 177 as previously described.[22] Bound human IgG antibodies were detected through sequential<br>178 steps using Fc-specific HRP-conjugated secondary antibodies and substrate. steps using Fc-specific HRP-conjugated secondary antibodies and substrate.

## <sup>179</sup>**Transfected-cell based assays**

180 HEK293 cells were transfected overnight using JetPEI with mammalian expression vectors<br>181 encoding human AHNAK2, ANXA2, CD44S, CNTN1, CASPR1, GFRA1, ITGA6, ITGA7, 181 encoding human AHNAK2, ANXA2, CD44S, CNTN1, CASPR1, GFRA1, ITGA6, ITGA7, 182<br>182 MAG, NEP, NFASC, NKCC1, PRX, TGBR3 (Supplementary Table 3), or using <sup>182</sup>MAG, NEP, NFASC, NKCC1, PRX, TGBR3 (**Supplementary Table 3**), or using 183 Lipofectamine 2000 for human ALCAM, AXL, DPYSL2, GAS6, L1CAM, NCAM1 and NrCAM<br>184 (Supplementary Table 4). Sera were diluted 1:100 and IgG binding was assessed using <sup>184</sup>(**Supplementary Table 4**). Sera were diluted 1:100 and IgG binding was assessed using fluorescent-conjugated anti-human IgG secondary antibodies.

## <sup>186</sup>**Statistical analysis**

187 The results were analysed in Prism v9.1.0 (GraphPad). Statistical comparisons of the<br>188 proportions of seropositive patients among ZIKV groups were performed using contingency 188 proportions of seropositive patients among ZIKV groups were performed using contingency<br>189 analyses with the application of a two-tailed Fisher's exact test for individual group-group 189 analyses with the application of a two-tailed Fisher's exact test for individual group-group<br>190 comparisons, and Chi square testing for comparisons between all groups. comparisons, and Chi square testing for comparisons between all groups.

192

193

#### <sup>194</sup>**RESULTS**

## <sup>195</sup>**Patient cohorts**

196 Serum samples were obtained from a total of 218 Colombian subjects: 52 patients with GBS<br>197 and confirmed ZIKV infection (ZIKV-GBS). 17 patients with ZIKV infection and other 197 and confirmed ZIKV infection (ZIKV-GBS), 17 patients with ZIKV infection and other<br>198 inflammatory neurological diseases (ZIKV-OND). 117 ZIKV-infected patients without 198 inflammatory neurological diseases (ZIKV-OND), 117 ZIKV-infected patients without<br>199 neurological complications (ZIKV-CON), and a control group (CON) formed by 23 patients 199 neurological complications (ZIKV-CON), and a control group (CON) formed by 23 patients<br>200 with Dengue virus (DENV) infections (DENV-CON) from Cali and 9 healthy controls from 200 with Dengue virus (DENV) infections (DENV-CON) from Cali and 9 healthy controls from<br>201 Cucuta. An additional 38 serum samples (5 ALS and 5 Dysferlin patients. and 28 healthy <sup>201</sup>Cucuta**.** An additional 38 serum samples (5 ALS and 5 Dysferlin patients, and 28 healthy 202 controls) from Spanish subjects and 21 healthy controls from the UK were also used<br>203 (Supplementary Figure 1). **(Supplementary Figure 1).** 

204 Overall, the patients with ZIKV-GBS were slightly older and less often female<br>205 (Supplementary Table 1). ZIKV capture ELISA showed the presence of anti-ZIKV lgG in all <sup>205</sup>(**Supplementary Table 1**). ZIKV capture ELISA showed the presence of anti-ZIKV IgG in all 206 ZIKV-GBS, ZIKV-OND and ZIKV-CON patients' sera tested, as well as the DENV patients'<br>207 sera, probably due to the likely cross-reactivity of DENV and ZIKV patients' antibodies [22] 207 sera, probably due to the likely cross-reactivity of DENV and ZIKV patients' antibodies [22] 208 (Supplementary Figure 2). <sup>208</sup>(**Supplementary Figure 2**).

#### <sup>209</sup>**Microarray screening for glycolipid complex antibodies**

210 ZIKV-associated patients' sera were screened against a panel of glycolipids using a<br>211 combinatorial glycoarray for the presence of lgG (Supplementary Figure 3A) and lgM 211 combinatorial glycoarray for the presence of IgG (**Supplementary Figure 3A**) and IgM<br>212 (**Supplementary Figure 3B**) anti-glycolipid antibodies. (Supplementary Figure 3B) anti-glycolipid antibodies.

213 Overall, the glycolipid array revealed only weak binding intensities against the panel of 136<br>214 Unique glycolipid targets, including known gangliosides implicated in GBS, none of which 214 unique glycolipid targets, including known gangliosides implicated in GBS, none of which<br>215 vere found to be statistically associated with post-ZIKV GBS. Two ZIKV-GBS samples were 215 were found to be statistically associated with post-ZIKV GBS. Two ZIKV-GBS samples were<br>216 found to contain IgG antibodies against various gangliosides at elevated levels, as typically 216 found to contain IgG antibodies against various gangliosides at elevated levels, as typically<br>217 seen in GBS and its clinical variants. This included a single ZIKV-GBS sample with anti-217 seen in GBS and its clinical variants. This included a single ZIKV-GBS sample with anti-<br>218 disialosyl IqG (GQ1b, GT1a and GD3) normally associated with the GBS subtype Miller-218 disialosyl IgG (GQ1b, GT1a and GD3) normally associated with the GBS subtype Miller-<br>219 Fisher syndrome: another with anti-GM1 IgG, typically present in the clinical subtype AMAN. 219 Fisher syndrome; another with anti-GM1 IgG, typically present in the clinical subtype AMAN.<br>220 It is possible that these cases may represent a temporal co-infection of Campylobacter and 220 It is possible that these cases may represent a temporal co-infection of Campylobacter and<br>221 Flavivirus, resulting in a classic lgG antibody signature for these patients. Flavivirus, resulting in a classic IgG antibody signature for these patients.

## <sup>222</sup>**Screening against rat DRG neurons and Schwann cells**

223 Moderate or strongly rat DRG reactive IgM autoantibodies were observed in proportionally<br>224 more sera of ZIKV-GBS patients compared to the ZIKV-OND. ZIKV-CON patients and other

more sera of ZIKV-GBS patients compared to the ZIKV-OND, ZIKV-CON patients and other

225 controls (CON) groups (Table 1). On the other hand, moderate or strong IgG autoantibody<br>226 reactivity against DRG neurons were not statistically different between these groups. With 226 reactivity against DRG neurons were not statistically different between these groups. With<br>227 the SCs, a greater proportion of moderate or strong IgG and IgM reactivity was observed in 227 the SCs, a greater proportion of moderate or strong IgG and IgM reactivity was observed in<br>228 ZIKV-GBS patients' sera compared to other uncomplicated ZIKV patients and control groups 228 ZIKV-GBS patients' sera compared to other uncomplicated ZIKV patients and control groups<br>229 (Table 1). <sup>229</sup>(**Table 1**).

230 Overall, there was a greater chance of observing any anti-peripheral nerve cell IgG or IgM<br>231 antibody reactivity in the ZIKV-GBS and ZIKV-OND patients' sera. compared to non-231 antibody reactivity in the ZIKV-GBS and ZIKV-OND patients' sera, compared to non-<br>232 complicated ZIKV (ZIKV-CON) and non-ZIKV control (CON) groups. These differences 232 complicated ZIKV (ZIKV-CON) and non-ZIKV control (CON) groups. These differences<br>233 between groups were statistically significant (p=0.0009. Chi square test). between groups were statistically significant (p=0.0009, Chi square test).

234 Additionally, we observed that IgG and IgM binding to DRG neurons or SCs were<br>235 significantly more common in the ZIKV-GBS patients' sera than in the ZIKV-CON group's 235 significantly more common in the ZIKV-GBS patients' sera than in the ZIKV-CON group's<br>236 sera (p=0.0042, Fisher's exact test); whereas there was no significant difference in the 236 sera (p=0.0042, Fisher's exact test); whereas there was no significant difference in the<br>237 proportions of grouped anti-ZIKV sera and non-ZIKV sera (p>0.05. Fisher's exact test) (see 237 proportions of grouped anti-ZIKV sera and non-ZIKV sera (p>0.05, Fisher's exact test) (see<br>238 **Figure 1** for multiple comparisons). **Figure 1** for multiple comparisons).

# <sup>239</sup>**Table 1. Statistical analysis of serum immunoreactivity to DRG neurons and SC**  <sup>240</sup>**cultures.**



241

## <sup>242</sup>**Screening against myelinating co-cultures**

243 IgM binding to myelinating co-cultures was frequently detected with both the ZIKV-GBS<br>244 patients' and control group's sera (Table 2 and Supplementary Figure 2). IgM reactivity 244 patients' and control group's sera (**Table 2 and Supplementary Figure 2**). IgM reactivity<br>245 was observed against the abaxonal membranes of mvelinating SCs. axons. the processes of was observed against the abaxonal membranes of myelinating SCs, axons, the processes of<br>246 the non-mvelinating SCs, as well as outpouchings of mvelin (**Supplementary Figures 4A** 246 the non-myelinating SCs, as well as outpouchings of myelin (**Supplementary Figures 4A** <sup>247</sup> **and B**). Overall, there was no significant difference in the proportions of ZIKV-GBS patients' 247 **and B**). Overall, there was no significant difference in the proportions of ZIKV-GBS patients'<br>248 and control sera in terms of the frequency or pattern of positive laM reactivity (p=0.3374. 248 and control sera in terms of the frequency or pattern of positive IgM reactivity (p=0.3374,<br>249 Fisher' exact test) (see **Table 2** for multiple comparisons). IgM labelling of mvelin 249 Fisher' exact test) (see **Table 2** for multiple comparisons). IgM labelling of myelin<br>250 outpouchings varied in intensity between the samples (**Supplementary Figures 4C and D**). 250 outpouchings varied in intensity between the samples (**Supplementary Figures 4C and D**),<br>251 however, immunofluorescence intensity at the mvelin outpouchings normalised to the 251 however, immunofluorescence intensity at the myelin outpouchings normalised to the<br>252 internode (Supplementary Figures 4E and F) was not significantly different between the 252 internode (**Supplementary Figures 4E and F**) was not significantly different between the<br>253 ZIKV-GBS patients', the ZIKV-CON patients' or the healthy control group's serum sample 253 ZIKV-GBS patients', the ZIKV-CON patients' or the healthy control group's serum sample<br>254 (One way ANOVA, F(2,106)=0.7417, p=0.4788) (**Supplementary Figure 4G**). <sup>254</sup>(One way ANOVA, F(2,106)=0.7417, p=0.4788) (**Supplementary Figure 4G**).

# <sup>255</sup>**Table 2. Frequency and statistical analysis of myelinating co-culture**

<sup>256</sup>**immunoreactivity.** 



#### 259

260 IgG antibody reactivity was observed against different topographical domains within the co-<br>261 cultures. Four out of 52 (7.7%) ZIKV-GBS patients' sera contained IgG which bound the 261 cultures. Four out of 52 (7.7%) ZIKV-GBS patients' sera contained IgG which bound the<br>262 abaxonal membrane of a subset of mvelinating SCs (Table 2), whilst showing no reactivity 262 abaxonal membrane of a subset of myelinating SCs (**Table 2**), whilst showing no reactivity 263 against non-myelinating SCs or axons (Figures 2A and B). <sup>263</sup>against non-myelinating SCs or axons (**Figures 2A and B**).

264 IgG from one ZIKV-GBS patient serum (male, 16-20 years old) was deposited on non-<br>265 compact myelin at the paranodes and Schmidt-Lanterman incisures (Figure 2C). One ZIKV-265 compact myelin at the paranodes and Schmidt-Lanterman incisures (**Figure 2C**). One ZIKV-266 GBS patient's sera (patient A, male, 41-45 years old) labelled the axons of cultured neurons<br>267 and their IgG antibody deposition was particularly concentrated at the nodal axolemma 267 and their IgG antibody deposition was particularly concentrated at the nodal axolemma<br>268 (Figure 2D). These patterns of IgG autoantibody reactivity were never seen with the control <sup>268</sup>(**Figure 2D**). These patterns of IgG autoantibody reactivity were never seen with the control 269 sera. The serum of one ZIKV-CON patient (patient B, female, 41-45 years old) also<br>270 contained lgG antibodies, which gave an intense pattern of immunofluorescence over the 270 contained IgG antibodies, which gave an intense pattern of immunofluorescence over the<br>271 abaxonal membranes of all mvelinating SCs. and at the nodal microvilli (Figure 2E): no lgG 271 abaxonal membranes of all myelinating SCs, and at the nodal microvilli (**Figure 2E**); no IgG<br>272 labelling from patient B was present sensory neuron or SC monocultures (data not shown). 272 labelling from patient B was present sensory neuron or SC monocultures (data not shown).<br>273 Overall, IgG antibody reactivity against myelinating co-cultures was significantly more 273 Overall, IgG antibody reactivity against myelinating co-cultures was significantly more<br>274 common in ZIKV-GBS patients' sera (5/52: 9.6%) compared to all controls (1/187: 0.5%) 274 common in ZIKV-GBS patients' sera (5/52; 9.6%) compared to all controls (1/187; 0.5%)<br>275 (p=0.0021. Fisher's exact test) (see **Table 2** for multiple comparisons). <sup>275</sup>(p=0.0021, Fisher's exact test) (see **Table 2** for multiple comparisons).

## <sup>276</sup>**Assessment of ZIKV antibody-mediated axonopathy and demyelination**

277 We next investigated the pathological potential of IgG autoantibodies in the two serum<br>278 samples which reacted strongly against the cell co-cultures: patient A (Figure 2D) and 278 samples which reacted strongly against the cell co-cultures: patient A (**Figure 2D**) and<br>279 patient B (**Figure 2E**). The axon and nodal binding of lgG antibodies present in the patient 279 patient B (**Figure 2E**). The axon and nodal binding of IgG antibodies present in the patient 280 A's serum was exclusively of the laG1 subclass (**Supplementary Figure 5A**). The addition <sup>280</sup>A's serum was exclusively of the IgG1 subclass (**Supplementary Figure 5A**). The addition 281 of patient A's serum at a 1:100 dilution did not result in any axonal degeneration or other<br>282 visible morphological nerve injury in the presence of complement in 20% NHS compared to 282 visible morphological nerve injury in the presence of complement in 20% NHS compared to<br>283 that caused by a known complement-fixing anti-ganglioside IgM positive control antibody 283 that caused by a known complement-fixing anti-ganglioside IgM positive control antibody<br>284 (Supplementary Figure 5B). <sup>284</sup>(**Supplementary Figure 5B**).

285 Antibodies reactive to myelinating SCs in patient B's serum were also predominantly of the<br>286 IgG1 subclass, with some IgG4 autoantibody subclass reaction against either SC processes 186 IgG1 subclass, with some IgG4 autoantibody subclass reaction against either SC processes<br>187 or axons (**Supplementary Figure 6**). or axons (**Supplementary Figure 6**).

288 The addition of patient B's sera at a 1:100 dilution to co-cultures in the presence of 20%<br>289 NHS resulted in complement deposition (C3c) around myelin internodes, and myelin 289 NHS resulted in complement deposition (C3c) around myelin internodes, and myelin<br>290 fragmentation without apparent axonal degeneration (Figures 3A, B). Time-lapse imaging of <sup>290</sup>fragmentation without apparent axonal degeneration (**Figures 3A**, **B**). Time-lapse imaging of

291 fluoromyelin-stained internodes revealed retraction of the myelin from the node within hours<br>292 of exposure to the anti-ZIKV serum in the presence of complement (Fiqures 3C. D). After 292 of exposure to the anti-ZIKV serum in the presence of complement (**Figures 3C, D**). After<br>293 24h. multiple mvelin internodes were either lost completely or significantly fragmented 293 24h, multiple myelin internodes were either lost completely or significantly fragmented<br>294 compared to baseline (0h) (Fiqure 3E). Anti-ZIKV serum treatment of the mvelinating co-294 compared to baseline (0h) (**Figure 3E**). Anti-ZIKV serum treatment of the myelinating co-295 cultures in the presence of complement in the 20% NHS, but not anti-ZIKV serum or NHS<br>296 alone. led to a significant loss of mvelin coverage (Figure 3F), increased mvelin 296 alone, led to a significant loss of myelin coverage (Figure 3F), increased myelin<br>297 fragmentation (Figure 3G) and shortening of internode length (Figure 3H), thereby 297 fragmentation (Figure 3G) and shortening of internode length (Figure 3H), thereby<br>298 confirming the effect seen using the time-lapse imaging (Figure 3D). <sup>298</sup>confirming the effect seen using the time-lapse imaging (**Figure 3D**).

#### <sup>299</sup>**Antigen identification in myelinating co-cultures**

300 The nodal/axonal binding ZIKV-GBS sera of patient A (**Figure 4A**) showed a similar binding<br>301 pattern to sera from a separate study containing anti-CNTN1 antibodies (**Figure 4B**) [23]. 301 pattern to sera from a separate study containing anti-CNTN1 antibodies (**Figure 4B**) [23].<br>302 Both sera maintained a similar lgG binding pattern when reacted with neuronal 302 Both sera maintained a similar IgG binding pattern when reacted with neuronal<br>303 monocultures thereby confirming the neuronal origin of both the unknown ZIKV-GBS auto-303 monocultures, thereby confirming the neuronal origin of both the unknown ZIKV-GBS auto-<br>304 antigen (Figure 4C) and CNTN1 (Figure 4D). No immunolabelling was observed with 304 antigen (**Figure 4C**) and CNTN1 (**Figure 4D**). No immunolabelling was observed with 305 healthy control serum (Figure 4E). In accordance with the nodal laG labelling observed in 305 healthy control serum (**Figure 4E**). In accordance with the nodal IgG labelling observed in<br>306 the mvelinating cell co-cultures, we tested for the nodal/paranodal candidate neurofascin 306 the myelinating cell co-cultures, we tested for the nodal/paranodal candidate neurofascin<br>307 (NF) in cell-based assavs. Heterologous expression of NF155 and NF186 isoforms in a HEK <sup>307</sup>(NF) in cell-based assays. Heterologous expression of NF155 and NF186 isoforms in a HEK 308 cell-based assay confirmed their antigen-specific targeting by IgG1 antibodies in this ZIKV-<br>309 GBS patient's sera (Figures 4F, G) who had succumbed to lethal ZIKV-induced GBS. This 309 GBS patient's sera (**Figures 4F, G**) who had succumbed to lethal ZIKV-induced GBS. This<br>310 fanti-pan-NF protein isoform' lgG autoreactivity pattern was not detected in any of the other 310 'anti-pan-NF protein isoform' IgG autoreactivity pattern was not detected in any of the other<br>311 ZIKV-GBS patients' or control sera. ZIKV-GBS patients' or control sera.

#### <sup>312</sup>**Immunoprecipitation**

313 We employed a proteomic approach to identify candidate antigens from our live cell culture<br>314 screening by isolating antigen-bound IgG antibodies from serum-treated cultures using 314 screening by isolating antigen-bound IgG antibodies from serum-treated cultures using<br>315 protein G bead immunoprecipitation (IP) followed by high resolution C18 reversed-phase 315 protein G bead immunoprecipitation (IP) followed by high resolution C18 reversed-phase<br>316 chromatography mass spectrometry (MS) analyses. We first validated this approach using 316 chromatography mass spectrometry (MS) analyses. We first validated this approach using<br>317 patient A's serum in neuronal cell monocultures. Three potential antigens were identified as 317 patient A's serum in neuronal cell monocultures. Three potential antigens were identified as<br>318 enriched in the IP: NF. NCAM1. and NCAM2 (Supplementary Data - Tab 1). confirming that 318 enriched in the IP: NF, NCAM1, and NCAM2 (**Supplementary Data - Tab 1**), confirming that 319 NF was a target antigen of patient A's serum. NF was a target antigen of patient A's serum.

320 The abaxonal SCs binding ZIKV-CON patient B's serum was compared with a patient with<br>321 anti-NF155 antibodies by IP-MS. which showed a similar pattern of lgG binding (Figures 5A. 321 anti-NF155 antibodies by IP-MS, which showed a similar pattern of IgG binding (**Figures 5A,** 322 **B, C and Supplementary Data – Tab 2**). A total of 28 proteins were significantly enriched **B, C and Supplementary Data – Tab 2**). A total of 28 proteins were significantly enriched

<sup>323</sup>by patient B's sera including some complement components and seven membrane-related <sup>324</sup>proteins: ANXA2, TGFBR3, NKCC1, NEP, CD44, ITGA6 and AHNAK2 (**Figure 5C**).

325 Sera from two of the ZIKV-GBS patients (patient C and patient D) which showed moderate<br>326 or strong reactivity against primary DRG neurons, and one from a healthy control, were also 326 or strong reactivity against primary DRG neurons, and one from a healthy control, were also<br>327 taken forward for IP-MS analysis. Antigen-bound IgG antibodies from patient C's sera ( 327 taken forward for IP-MS analysis. Antigen-bound IgG antibodies from patient C's sera **(**<br>328 **Supplementary Data - Tab 3)** and patient D's sera (**Supplementary Data – Tab 4**), or <sup>328</sup>**Supplementary Data - Tab 3)** and patient D's sera (**Supplementary Data – Tab 4**)**,** or 329 secondary IgG anti-IgM bound to patient D's IgM neurone autoreactive antibodies **(**<br>330 **Supplementary Data – Tab 5**) were isolated from DRG neurons lysates by IP and <sup>330</sup>**Supplementary Data – Tab 5**) were isolated from DRG neurons lysates by IP and 331 processed for MS. In this study, six potential autoantigens (ALCAM, DPYSL2, NCAM1, 332 CNTN1. L1CAM. VINC) were identified as enriched by these anti-ZIKV sera compared to the 332 CNTN1, L1CAM, VINC) were identified as enriched by these anti-ZIKV sera compared to the<br>333 control sera. control sera.

#### <sup>334</sup>**Evaluation of candidate antigens**

335 Candidate antigens identified by IP-MS were evaluated by either ELISA or by heterologous<br>336 expression in live cell-based assavs. ELISA using human recombinant prosaposin and GM3 336 expression in live cell-based assays. ELISA using human recombinant prosaposin and GM3<br>337 (alone or in combination), multiple human laminin isoforms and nidogen-1 failed to confirm 337 (alone or in combination), multiple human laminin isoforms and nidogen-1 failed to confirm<br>338 these as targets of patient B's serum lgG autoantibodies (**Supplementary Table 2**). <sup>338</sup>these as targets of patient B's serum IgG autoantibodies (**Supplementary Table 2**).

339 Heterologous expression in HEK cells failed to reveal binding of ZIKV-CON patient B's<br>340 serum lgG antibodies to ANXA2 (Figure 5D) or anv of the large number of other candidate 340 serum IgG antibodies to ANXA2 (**Figure 5D**) or any of the large number of other candidate<br>341 proteins in ELISA (**Supplementary Table 2**). Furthermore, neither ZIKV-GBS patient C's or 341 proteins in ELISA (**Supplementary Table 2**). Furthermore, neither ZIKV-GBS patient C's or<br>342 D's serum lgG or IgM antibodies reacted against anv of the candidate antigens by 342 D's serum IgG or IgM antibodies reacted against any of the candidate antigens by<br>343 beterologous expression in these cell-based assavs (**Supplementary Table 3**). We <sup>343</sup>heterologous expression in these cell-based assays (**Supplementary Table 3**). We 344 additionally analyzed IgG and IgM reactivity of anti-ZIKV sera against GAS6 and AXL<br>345 oroteins, which have been described as the receptors ZIKV virus entry to human neural cells 345 proteins, which have been described as the receptors ZIKV virus entry to human neural cells<br>346 as well as NrCAM, which shares 6 common peptide sequences with the ZIKV polyprotein. 346 as well as NrCAM, which shares 6 common peptide sequences with the ZIKV polyprotein.<br>347 However, none of these sera reacted against these three candidate antigens or members of 347 However, none of these sera reacted against these three candidate antigens or members of 348 the AXL-GAS6 complex (Supplementary Table 3). <sup>348</sup>the AXL-GAS6 complex (**Supplementary Table 3**).

349 To account for the potential loss of antigen during the IP process, we subjected the lysates<br>350 of myelinating cell co-cultures to electrophoresis on an acrylamide gel and after electro-350 of myelinating cell co-cultures to electrophoresis on an acrylamide gel and after electro-<br>351 blotting on nitrocellulose membranes the reactions of patient B's sera autoantibodies were 351 blotting on nitrocellulose membranes the reactions of patient B's sera autoantibodies were<br>352 tested against these nerve cell antigens. Through this western blotting analysis, the 352 tested against these nerve cell antigens. Through this western blotting analysis, the<br>353 patients' lgG antibodies reacted strongly with two bands (**Supplementary Figure 7**). Manual 353 patients' IgG antibodies reacted strongly with two bands (**Supplementary Figure 7**). Manual<br>354 filtering for membrane proteins associated with SCs or myelination identified three potential 354 filtering for membrane proteins associated with SCs or myelination identified three potential<br>355 target antigens: PRX. ITGA7 and GFRA1 (Supplementary Data – Tab 6). However, no lgG target antigens: PRX, ITGA7 and GFRA1 (Supplementary Data – Tab 6). However, no IgG

356 reactivity to these particular antigens was observed using patient B's serum on transiently-<br>357 transfected cell-based assavs (**Supplementary Table 2**).

<sup>357</sup>transfected cell-based assays (**Supplementary Table 2**).

#### <sup>358</sup>**Chemical and enzymatic characterisation of target antigens**

359 The intense labelling of the patient B's serum in the lipid rich membrane and nodal microvilli<br>360 of mvelinating SCs (Figure 6A) led us to further investigate the target antigen characteristics 360 of myelinating SCs (**Figure 6A**) led us to further investigate the target antigen characteristics<br>361 using a biochemical approach. Solvent extraction of lipids from serum-treated and fixed 361 using a biochemical approach. Solvent extraction of lipids from serum-treated and fixed<br>362 mvelinated co-cultures with mixture of chloroform. methanol and water as described 362 myelinated co-cultures with mixture of chloroform, methanol and water as described<br>363 previously [24] significantly reduced the amount of patient B's serum lgG antibodies which 363 previously [24] significantly reduced the amount of patient B's serum IgG antibodies which<br>364 bound to the abaxonal SCs membranes (Fiqure 6B. C and D), while the reactivity of 364 bound to the abaxonal SCs membranes (**Figure 6B, C and D**), while the reactivity of 365 commercial antibodies directed against NF2000 and MBP antigens were retained (**Figure** 365 commercial antibodies directed against NF2000 and MBP antigens were retained (**Figure** 366 **6B and C**). Solvent extraction did not affect labelling of human IgG to the GPI-linked protein 366 **6B and C**). Solvent extraction did not affect labelling of human IgG to the GPI-linked protein<br>367 CNTN1 (Supplementary Figure 8). Limited IgG antibody labeling remained at the 367 CNTN1 (**Supplementary Figure 8**). Limited IgG antibody labeling remained at the<br>368 paranodes (**Figure 6B**). Binding of patient B's lgG antibodies was not however affected by 368 paranodes (**Figure 6B**). Binding of patient B's IgG antibodies was not however affected by<br>369 prior neuraminidase treatment of the cell co-cultures (**Supplementary Figure 9**) compared 369 prior neuraminidase treatment of the cell co-cultures (**Supplementary Figure 9**) compared<br>370 with positive controls (**Supplementary Figure 10**) suggesting that the target antigen was not 370 with positive controls (**Supplementary Figure 10**) suggesting that the target antigen was not<br>371 a sialvlated glycolipid. a sialylated glycolipid.

372

### <sup>373</sup>**DISCUSSION**

374 Our study found that the humoral immune response in ZIKV-GBS cases was diverse and<br>375 heterogeneous. We found neither a common antigen nor a common pattern of serum 375 heterogeneous. We found neither a common antigen nor a common pattern of serum<br>376 immunoreactivity against peripheral nerve structures despite all of these ZIKV-GBS patients 376 immunoreactivity against peripheral nerve structures despite all of these ZIKV-GBS patients<br>377 sharing a common prodromal infection. sharing a common prodromal infection.

378 Consistent with a recent study of a modest cohort of ZIKV-associated GBS patients from<br>379 Brazil.[11] we observed a small number of GBS patients with elevated anti-glycolipid IgG 379 Brazil,[11] we observed a small number of GBS patients with elevated anti-glycolipid IgG<br>380 antibodies. However, we did not find a significant statistical association of ZIKV-GBS patient 380 antibodies. However, we did not find a significant statistical association of ZIKV-GBS patient<br>381 cases with any anti-glycolipid antibody signature, thereby supporting the results from a 381 cases with any anti-glycolipid antibody signature, thereby supporting the results from a<br>382 recent cohort study from Northeast Brazil. [25] The cases we did find may represent a 382 Fecent cohort study from Northeast Brazil. [25] The cases we did find may represent a<br>383 Subset of ZIKV induced GBS, or merely have been cases of classical onset GBS patients 383 subset of ZIKV induced GBS, or merely have been cases of classical onset GBS patients<br>384 whose clinical course coincided with recent ZIKV infections. whose clinical course coincided with recent ZIKV infections.

385 Analysis of the ZIKV polyprotein showed that it contained peptide sequences which were<br>386 also found in human proteins and that are known to be targets of inflammatory neuropathy also found in human proteins and that are known to be targets of inflammatory neuropathy

387 autoantibodies.[26] However, while all ZIKV patient samples tested contained anti-ZIKV IgG<br>388 antibodies. anti-nerve reactive autoantibodies showed a more discrete distribution. 388 antibodies, anti-nerve reactive autoantibodies showed a more discrete distribution,<br>389 suggesting that any nerve-related antigenicity was not a conseguence of humoral immunity 389 suggesting that any nerve-related antigenicity was not a consequence of humoral immunity<br>390 to ZIKV antigens *per se*. Despite the high level of antigenic similarity between flaviviruses. 390 to ZIKV antigens *per se*. Despite the high level of antigenic similarity between flaviviruses,<br>391 we did not observe anv specific nerve cell reactive autoantibodies in the DENV-infected 391 we did not observe any specific nerve cell reactive autoantibodies in the DENV-infected<br>392 control (DENV-CON) sera, in keeping with the rarity of GBS associated with recent DENV 392 control (DENV-CON) sera, in keeping with the rarity of GBS associated with recent DENV<br>393 infections.[27] Although we observed one case of anti-pan-NF protein isotype IgG1 393 infections.[27] Although we observed one case of anti-pan-NF protein isotype IgG1<br>394 autoantibodies in our Colombian cohort (ZIKV-GBS patient A). prodromal infection is not a 394 autoantibodies in our Colombian cohort (ZIKV-GBS patient A), prodromal infection is not a<br>395 consistent feature of this rare and potentially fatal peripheral neuropathy subtype.[28] <sup>395</sup>consistent feature of this rare and potentially fatal peripheral neuropathy subtype.[28]

396 By employing a comprehensive series of peripheral nerve cell culture models and antigen<br>397 expression systems, we reveal a surprisingly heterogeneous autoantibody response in 397 expression systems, we reveal a surprisingly heterogeneous autoantibody response in<br>398 patients' sera. Overall, IgG reactivity to rat SCs and the cell co-cultures was significantly 398 patients' sera. Overall, IgG reactivity to rat SCs and the cell co-cultures was significantly<br>399 bigher, albeit infrequently, in the ZIKV-GBS patient group compared to all controls. IgM 399 higher, albeit infrequently, in the ZIKV-GBS patient group compared to all controls. IgM<br>400 reactivity against rat DRG neurons and rat SCs was also significantly higher in ZIKV-GBS 400 reactivity against rat DRG neurons and rat SCs was also significantly higher in ZIKV-GBS<br>401 patient than in the control group. On the other hand. IgM immunoreactivity to mvelin 401 patient than in the control group. On the other hand, IgM immunoreactivity to myelin<br>402 outpouchings, a feature reminiscent of the myelin foldings, swellings or tomaculae 402 outpouchings, a feature reminiscent of the myelin foldings, swellings or tomaculae<br>403 sometimes seen in certain hereditary neuropathies.[29] was remarkably common in both the sometimes seen in certain hereditary neuropathies,[29] was remarkably common in both the<br>404 ZIKV-GBS patient and control groups. The significance of these structures in the co-culture 404 ZIKV-GBS patient and control groups. The significance of these structures in the co-culture<br>405 system is however unclear. system is however unclear.

406 One patient (ZIKV-CON patient B), with an uncomplicated ZIKV infection, displayed striking<br>407 IdG reactivity against abaxonal membrane of myelinating SCs that was particularly enriched 407 IgG reactivity against abaxonal membrane of myelinating SCs that was particularly enriched<br>408 at the nodal villi. These lgG1 subclass antibodies induced profound demvelination in our in <sup>408</sup>at the nodal villi. These IgG1 subclass antibodies induced profound demyelination in our *in*  409 vitro model system via a complement-dependent pathway, despite the patient lacking<br>410 neurological symptoms. This apparent functional discrepancy might be accounted for by the 410 neurological symptoms. This apparent functional discrepancy might be accounted for by the<br>411 use of rodent SCs in the co-culture system and a potential lack of cross-reactivity to human 411 use of rodent SCs in the co-culture system and a potential lack of cross-reactivity to human<br>412 SCs. or by the target antigen(s) remaining hidden from circulating antibodies *in situ*. <sup>412</sup>SCs, or by the target antigen(s) remaining hidden from circulating antibodies *in situ*.

413 By employing IP-MS in sera-treated myelinating co-cultures and DRG neurons, we revealed<br>414 a number of candidate antigens related to either SC membranes, myelin formation, or neural 414 a number of candidate antigens related to either SC membranes, myelin formation, or neural<br>415 cell adhesion. However, we could not confirm any candidate antigen reactivity by these 415 cell adhesion. However, we could not confirm any candidate antigen reactivity by these<br>416 patients lgG or lgM antibodies by either the ELISA or cell-based assavs, reinforcing the 416 patients IgG or IgM antibodies by either the ELISA or cell-based assays, reinforcing the<br>417 challenges of antigen identification in the inflammatory neuropathies.[30] Nevertheless, the 417 challenges of antigen identification in the inflammatory neuropathies.[30] Nevertheless, the<br>418 patterns of immunoreactivity specific to the patient groups, such as nodal, axonal and myelin 418 patterns of immunoreactivity specific to the patient groups, such as nodal, axonal and myelin<br>419 internodes in the mvelinating co-cultures, which were not observed in anv control samples. internodes in the myelinating co-cultures, which were not observed in any control samples,

420 suggest that the near-native antigen conformation in the cell co-culture system is a high-<br>421 fidelity substrate for screening potentially pathogenic patients' serum lgG antibodies.[19]

421 fidelity substrate for screening potentially pathogenic patients' serum IgG antibodies.[19]<br>422

422 One of the limitations of our study is that our protocols are optimized for proteins and not for<br>424 lipids. In fact. solvent-based lipid extraction significantly reduced reactivity of patient B's lgG 424 lipids. In fact, solvent-based lipid extraction significantly reduced reactivity of patient B's IgG<br>425 autoantibody reactions against myelinating SCs in the co-culture system, suggesting a 425 autoantibody reactions against myelinating SCs in the co-culture system, suggesting a<br>426 lipidomic approach may be required. It is also possible that certain protein antigens were not 426 lipidomic approach may be required. It is also possible that certain protein antigens were not<br>427 detectable, either due to poor immunoprecipitation, or lack of representation in the peptide 427 detectable, either due to poor immunoprecipitation, or lack of representation in the peptide<br>428 database used to compile our list of candidate antigens. An alternative approach is offered 428 database used to compile our list of candidate antigens. An alternative approach is offered<br>429 by high throughput antibody screening techniques such as the newly described Rapid 429 by high throughput antibody screening techniques such as the newly described Rapid<br>430 Extracellular Antigen Profiling (REAP) technique. [31, 32] or chip-based proteome profiling 430 Extracellular Antigen Profiling (REAP) technique,[31, 32] or chip-based proteome profiling<br>431 1331, which has recently offered insights into the autoantibody repertoire of patients with <sup>431</sup>[33], which has recently offered insights into the autoantibody repertoire of patients with 432 chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).[34]<br>433

433 Ablahfald our findings mirror our recent screening of a separate cohort of 100 GBS patients, where we<br>Ablahfald report a similarly heterogeneous reactivity of lgG and lgM to nerve-related antigens.[35] The 435 report a similarly heterogeneous reactivity of IgG and IgM to nerve-related antigens.[35] The<br>436 narrow definition of the present GBS cohort. in which all patients associated with the same 436 anarrow definition of the present GBS cohort, in which all patients associated with the same<br>437 antectious insult, suggest that heterogeneity of the humoral immune responses in GBS may 437 infectious insult, suggest that heterogeneity of the humoral immune responses in GBS may<br>438 be a core feature of the disease and not necessarily due to heterogeneity of the patient 438 be a core feature of the disease and not necessarily due to heterogeneity of the patient 439 cohorts. cohorts.

#### <sup>440</sup>**Acknowledgements**

441 We thank Professors Peter Brophy and Sarosh Irani for kindly providing the periaxin<br>442 antibody and healthy human control sera, respectively. We also thank Professor Robert 442 antibody and healthy human control sera, respectively. We also thank Professor Robert<br>443 MacLaren, Dr Tina Storm and Dr Ahmed Salman for their generous assistance with the 443 MacLaren, Dr Tina Storm and Dr Ahmed Salman for their generous assistance with the<br>444 IncuCvte time-lapse imaging. The authors would like to acknowledge the Department of 444 IncuCyte time-lapse imaging. The authors would like to acknowledge the Department of<br>445 Medicine at the Universitat Autònoma de Barcelona. CLI and LQ are members of the 445 Medicine at the Universitat Autònoma de Barcelona. CLI and LQ are members of the<br>446 European Reference Network for Neuromuscular Diseases - Proiect ID No. 870177. pCSC-446 European Reference Network for Neuromuscular Diseases - Project ID No. 870177. pCSC-<br>447 SP-PW-Nep (aka: pBOB-NEP) was a gift from Inder Verma. CD44S pBabe-puro was a gift 447 SP-PW-Nep (aka: pBOB-NEP) was a gift from Inder Verma. CD44S pBabe-puro was a gift<br>448 from Bob Weinberg, anxA2-GFP was a gift from Volker Gerke & Ursula Rescher, ITGA6-bio-448 from Bob Weinberg. anxA2-GFP was a gift from Volker Gerke & Ursula Rescher. ITGA6-bio-449 His was a gift from Gavin Wright. pcDNA3.1 Flag YFP hNKCC1 (NT17) was a gift from Biff<br>450 Forbush. pBabe neo TGFBR3-HA was a gift from Kevin Janes. Forbush. pBabe neo TGFBR3-HA was a gift from Kevin Janes.

# <sup>451</sup>**Competing interests**

452 SR has received a) a speaker's honoraria from Fresenius, Alnylam and Excemed, and<br>453 Davments to provide expert medicolegal advice on inflammatory neuropathies and their payments to provide expert medicolegal advice on inflammatory neuropathies and their

454 treatment, b) a complimentary registration and prize money from the Peripheral Nerve<br>455 Society and c) a travel bursary from the European School of Neuroimmunology and is a 455 Society and c) a travel bursary from the European School of Neuroimmunology and is a<br>456 member of the GBS and Associated Inflammatory Neuropathies (GAIN) patient charity 456 member of the GBS and Associated Inflammatory Neuropathies (GAIN) patient charity<br>457 medical advisory board. He also runs a not-for-profit nodal/paranodal antibody testing 457 medical advisory board. He also runs a not-for-profit nodal/paranodal antibody testing<br>458 service at the Nuffield Department of Clinical Neurosciences. John Radcliffe Hospital. 458 service at the Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital,<br>459 Oxford. UK. in partnership with Clinical Laboratory Immunology of Oxford University 459 Oxford, UK, in partnership with Clinical Laboratory Immunology of Oxford University<br>460 Hospitals. 460 Hospitals.<br>461

462

## 462

463 **Funding**<br>464 This work <sup>464</sup>This work is supported by the Medical Research Council UK (MR/P008399/1) (S.R.); *Fondo*  <sup>465</sup>*de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III*, Spain and FEDER under 466 grant FIS19/01407 and INT20/00080; Wellcome Grant 092805 (S.K.H. and H.J.W.) and by<br>467 the GBS-CIDP Foundation International. AKF. CMR. LO. BP. CAP. DG. SKH and HJW were 467 the GBS-CIDP Foundation International. AKF, CMR, LO, BP, CAP, DG, SKH and HJW were<br>468 also members of a European Union's Horizon 2020 Research and Innovation Program 468 also members of a European Union's Horizon 2020 Research and Innovation Program<br>469 ZikaPLAN grant agreement 734584 and 202789 under which many of the ZIKV-GBS. ZIKV-469 ZikaPLAN grant agreement 734584 and 202789 under which many of the ZIKV-GBS, ZIKV-<br>470 OND. ZIKV-CON and DENV-CON patients were clinically diagnosed and their serum 470 OND, ZIKV-CON and DENV-CON patients were clinically diagnosed and their serum<br>471 samples were collected and initially assessed before being transferred to the UK for 471 samples were collected and initially assessed before being transferred to the UK for<br>472 inclusion in this study. 472 inclusion in this study.<br>473

473

## <sup>475</sup>**Figure legends**

# <sup>476</sup>**Figure 1. Reactivity of ZIKV patients' serum IgG and IgM antibodies against primary**  <sup>477</sup>**cultured rat DRG neurons and Schwann cells.**

478 Immunofluorescent assay photomicrographs using ZIKV-GBS patients' serum samples<br>479 showing strong lgG (A) or lgM (B) antibody reactivity against DRG neurons, strong lgG (C) 479 showing strong IgG (**A**) or IgM (**B**) antibody reactivity against DRG neurons, strong IgG (**C**) 480 and IgM (**D**) antibody reactivity against Schwann cells compared to the negative control 480 and IgM (D) antibody reactivity against Schwann cells compared to the negative control<br>481 (CON) human sera which showed negligible/weak non-specific lgG (E) or lgM (F) antibody <sup>481</sup>(CON) human sera which showed negligible/weak non-specific IgG (**E**) or IgM (**F**) antibody <sup>482</sup>reactivity against DRG neurons or IgG (**G**) or IgM (**H**) antibody reactivity against Schwann 483 cells. The percentage of IgG and IgM reactive antibodies of different intensities (0 = 484 negative, 1 = weak, 2 = moderate and 3 = strong) from the different human patient groups 484 negative, 1 = weak, 2 = moderate and 3 = strong) from the different human patient groups<br>485 (ZIKV-GBS, ZIKV-OND, ZIKV-CON and healthy controls (CON)) against DRG neurons, 485 (ZIKV-GBS, ZIKV-OND, ZIKV-CON and healthy controls (CON)) against DRG neurons,<br>486 Schwann cells (SCs) or either DRG/SCs are shown in **I. J** and **K** respectively and the p-486 Schwann cells (SCs) or either DRG/SCs are shown in **I**, **J** and **K** respectively and the pvalues of  $< 0.05$ ,  $< 0.01$  or  $< 0.001$  are shown as \*, \*\*, and \*\*\* respectively.

# 488 **Figure 2. Patterns of ZIKV patients' serum IgG reactivity against myelinating cell co-**<sup>489</sup>**cultures.**

490 Examples of immunofluorescent photomicrographs of IgG binding patterns (green) of 491 different ZIKV-GBS and ZIKV-CON patients' sera in myelinated nerve cell cultures. (A) The 491 different ZIKV-GBS and ZIKV-CON patients' sera in myelinated nerve cell cultures. (**A**) The<br>492 selective labelling of individual internodes by IgG antibodies from one female ZIKV-GBS 492 selective labelling of individual internodes by IgG antibodies from one female ZIKV-GBS<br>493 patient (ZN060A, 31-35 vears old) with the AMAN subtype (a similar IgG binding pattern was 493 patient (*ZN060A*, 31-35 years old) with the AMAN subtype (a similar IgG binding pattern was<br>494 seen in one other male ZIKV-GBS patient (*Cali006*, 41-45 years old). (**B**) Myelin 494 seen in one other male ZIKV-GBS patient (*Cali006*, 41-45 years old). (**B**) Myelin<br>495 outpouchings or 'blebs' labelled by lgG autoantibodies in the serum of a female ZIKV-GBS 495 outpouchings or 'blebs' labelled by IgG autoantibodies in the serum of a female ZIKV-GBS<br>496 patient (patient D. ZN005A. 46-50 vears old) with the AIDP subtvpe. (C) Mvelin paranodes 496 patient (patient D, *ZN005A*, 46-50 years old) with the AIDP subtype. (C) Myelin paranodes<br>497 (arrows) and Schmidt-Lanterman incisors (arrow heads) labelled by lgG autoantibody 497 (arrows) and Schmidt-Lanterman incisors (arrow heads) labelled by IgG autoantibody<br>498 reactions from the serum of a male ZIKV-GBS patient (*ZN039A*, 16-20 years old) with AIDP 198 reactions from the serum of a male ZIKV-GBS patient (*ZN039A*, 16-20 years old) with AIDP<br>199 subtype. (D) Axonal and labelling with enrichment at the node shown by lgG autoantibody 499 subtype. (D) Axonal and labelling with enrichment at the node shown by IgG autoantibody<br>500 reactions from the serum of a male ZIKV-GBS patient (patient A, Cali077, 41-45 years old) 500 reactions from the serum of a male ZIKV-GBS patient (patient A, *Cali077*, 41-45 years old)<br>501 fatal case. Nodal regions corresponding to insets in (C) and (D) are shown on the far right. 501 fatal case. Nodal regions corresponding to insets in (C) and (D) are shown on the far right.<br>502 (E) The labelling of the abaxonal membranes of all mvelinating Schwann cells by the lgG 502 (E) The labelling of the abaxonal membranes of all myelinating Schwann cells by the IgG<br>503 autoantibodies in the serum of a female ZIKV-CON patient (patient B. BQ008, 41-45 vears 503 autoantibodies in the serum of a female ZIKV-CON patient (patient B, *BQ008*, 41-45 years<br>504 old) with previous uncomplicated ZIKV infection. Note that the staining is particularly intense 504 old) with previous uncomplicated ZIKV infection. Note that the staining is particularly intense<br>505 at the Schwann cell microvilli overlying the node of Ranvier (right). Co-cultures are 505 at the Schwann cell microvilli overlying the node of Ranvier (right). Co-cultures are<br>506 counterstained with NF200 (blue) and mvelin basic protein (MBP) (red). Scale bars 5. 10 or 506 counterstained with NF200 (blue) and myelin basic protein (MBP) (red). Scale bars 5, 10 or<br>507 20 um as indicated.  $20 \mu m$  as indicated.

#### <sup>508</sup>**Figure 3. Complement-dependent demyelinating activity of ZIKV patients' sera.**

509 The autoantibodies in the sera of ZIKV-CON patient B reacted with myelin internodes and<br>510 fixed complement (C3c deposition; green) over myelin internodes (MBP; red) when 510 fixed complement (C3c deposition; green) over myelin internodes (MBP; red) when<br>511 complement was present from 20% normal human sera (NHS) (A) but not when only NHS 511 complement was present from 20% normal human sera (NHS) (A) but not when only NHS<br>512 vas added to the cells (B). Counterstaining for NF200 (blue) and MBP (red) are also shown. 512 was added to the cells (**B**). Counterstaining for NF200 (blue) and MBP (red) are also shown.<br>513 (C) Fluoromvelin labelling (red) from live imaging of a mvelinated co-culture before (above) <sup>513</sup>(**C**) Fluoromyelin labelling (red) from live imaging of a myelinated co-culture before (*above*) 514 and 16h after (*below*) incubation with patient B's serum at a 1:50 dilution in the presence of<br>515 complement in 20% NHS, while (D) shows the results of time-lapse stills of the receding 515 complement in 20% NHS, while (**D**) shows the results of time-lapse stills of the receding<br>516 mvelin internode iunctions shown from right to left over time (arrows). (**E/E**') shows the 516 myelin internode junctions shown from right to left over time (arrows). (**E/E**') shows the<br>517 overlaid example images of live myelin staining at baseline (red) and after 24h incubation 517 overlaid example images of live myelin staining at baseline (red) and after 24h incubation<br>518 (silver) with patient B's serum with or without 20% containing complement. (E') shows 518 (silver) with patient B's serum with or without 20% containing complement. (**E**') shows<br>519 numerous myelin internodes are either lost completely or extensively fragmented after 24h 519 numerous myelin internodes are either lost completely or extensively fragmented after 24h<br>520 (shown by arrows), while (E) without NHS containing complement the distribution of the 520 (shown by arrows), while (**E**) without NHS containing complement the distribution of the<br>521 mvelin was essentially unchanged over 24h. (F) The total mvelin length was reduced at 24h 521 myelin was essentially unchanged over 24h. (F) The total myelin length was reduced at 24h<br>522 (F. \*\*\* p<0.001. one-way ANOVA with Bonferroni correction). (G) The number of myelin <sup>522</sup>(**F,** \*\*\* p<0.001, one-way ANOVA with Bonferroni correction). (**G**) The number of myelin 523 segments increased, (G, \*p<0.05, one-way ANOVA with Bonferroni correction) in cultures<br>524 treated with patient B's serum with NHS containing complement compared to all control 524 treated with patient B's serum with NHS containing complement compared to all control<br>525 conditions (n=3 per group). (H) The mean internodal length was also significantly reduced at 525 conditions (n=3 per group). (**H**) The mean internodal length was also significantly reduced at<br>526 24h compared to baseline in ZIKV-CON+NHS group only (**H**, \*\*\*\*p<000.1, 2-way ANOVA 526 24h compared to baseline in ZIKV-CON+NHS group only (**H**, \*\*\*\*p<000.1, 2-way ANOVA<br>527 with Sidak's correction). with Sidak's correction).

# <sup>528</sup>**Figure 4. Transfected cell-based assays confirm pan-neurofascin reactivity of IgG**  <sup>529</sup>**antibodies within the serum of a patient with fatal, ZIKV-associated GBS**.

530 Immunofluorescent photomicrographs of (A) ZIKV-GBS patient A's serum antibodies,<br>531 reactive to unknown antigen enriched in axolemma and (B) a positive control patient's serum 531 reactive to unknown antigen enriched in axolemma and (**B**) a positive control patient's serum<br>532 with autoantibodies against the known nerve membrane antigen CNTN1 showed strong lgG 532 with autoantibodies against the known nerve membrane antigen CNTN1 showed strong IgG<br>533 (green) reactions against myelinated co-cultures, as well as in neuronal monocultures 533 (green) reactions against myelinated co-cultures, as well as in neuronal monocultures<br>534 treated with (C) patients A's serum. (D) the anti-CNTN1+ serum. (E) Healthy control serum 534 treated with (C) patients A's serum, (D) the anti-CNTN1+ serum. (E) Healthy control serum<br>535 was negative. Patient A's IgG serum autoantibodies also reacted with HEK cells expressing 535 was negative. Patient A's IgG serum autoantibodies also reacted with HEK cells expressing<br>536 the recombinant the NK155 (F) and NF186 (G) protein isoforms. Co-cultures are 536 the recombinant the NK155 (F) and NF186 (G) protein isoforms. Co-cultures are<br>537 counterstained with NF200 (blue) and mvelin basic protein (MBP) (red). Scale bars. 20 and 537 counterstained with NF200 (blue) and myelin basic protein (MBP) (red). Scale bars, 20 and 538 50 um as shown. 50 µm as shown.

# <sup>540</sup>**Figure 5. Identification of a ZIKV patient's autoantibodies against myelin antigen:**  Immunoprecipitation and peptide mass spectrometry.

542 Immunofluorescent photomicrographs of (A) a positive control patient's serum with<br>543 autoantibodies against the known nerve antigen NF155 and (B) ZIKV-CON patient B's 543 autoantibodies against the known nerve antigen NF155 and **(B**) ZIKV-CON patient B's<br>544 serum autoantibody reactions against unknown antigens enriched in abaxonal myelin. with 544 serum autoantibody reactions against unknown antigens enriched in abaxonal myelin, with<br>545 higher magnifications of the nodal regions shown as insets (far right). Scale bars. 20 um. 545 higher magnifications of the nodal regions shown as insets (far right). Scale bars, 20 µm.<br>546 Counterstaining for NF200 (blue) and MBP (red) are also shown. (C) Proteins identified in 546 Counterstaining for NF200 (blue) and MBP (red) are also shown. (C) Proteins identified in<br>547 immunoprecipitates from ZIKV serum and NF155+ serum-treated co-culture lysates. t-test of 547 immunoprecipitates from ZIKV serum and NF155+ serum-treated co-culture lysates. t-test of<br>548 enriched proteins presented as a volcano plot. iPSC lines from four donors were used to 548 enriched proteins presented as a volcano plot. iPSC lines from four donors were used to<br>549 aenerate mvelinating co-cultures, and immunoprecipitates were purified and analysed by 549 generate myelinating co-cultures, and immunoprecipitates were purified and analysed by<br>550 mass spectrometry to give four biological replicates per serum sample. Significant data 550 mass spectrometry to give four biological replicates per serum sample. Significant data<br>551 points were determined with a permutation-based false discovery rate (FDR) calculation 551 points were determined with a permutation-based false discovery rate (FDR) calculation<br>552 (threshold = 0.1) and the significantly enriched membrane proteins are shown as red 552 (threshold = 0.1) and the significantly enriched membrane proteins are shown as red<br>553 squares NFASC (neurofascin) protein isoforms from a human and rat database are grouped 553 squares. NFASC (neurofascin) protein isoforms from a human and rat database are grouped<br>554 together (blue circle). TGBR3. transforming growth factor receptor 3: AHNAK2. desmovokin: 554 together (blue circle). TGBR3, transforming growth factor receptor 3; AHNAK2, desmoyokin;<br>555 SLC12A2, solute carrier 12/Na-K-2Cl cotransporter A2: NEP, neprilvsin: CD44, P-555 SLC12A2, solute carrier 12/Na-K-2Cl cotransporter A2; NEP, neprilysin; CD44, P-<br>556 glycoprotein 1: ITGA6, integrin alpha 6. The remaining peptides were identified as either 556 glycoprotein 1; ITGA6, integrin alpha 6. The remaining peptides were identified as either<br>557 serum components (immunoalobulin or complement proteins) or intracellular proteins. (D) 557 serum components (immunoglobulin or complement proteins) or intracellular proteins. (D)<br>558 ZIKV-CON patient B's serum autoantibodies were however shown to be unreactive with the 558 ZIKV-CON patient B's serum autoantibodies were however shown to be unreactive with the<br>559 ANXA2 calcium binding membrane binding protein expressed in transfected HEK cells using 559 ANXA2 calcium binding membrane binding protein expressed in transfected HEK cells using<br>560 immunofluorescent photomicrographic analysis. immunofluorescent photomicrographic analysis.

# <sup>561</sup>**Figure 6. Removal of ZIKV-CON patient B's serum IgG autoantibody target antigen(s)**  <sup>562</sup>**in myelinated sensory neuron cultures by lipid extraction.**

<sup>563</sup>(**A**) Immunofluorescent photomicrographs of ZIKV-CON patient B's serum IgG 564 autoantibodies showing strong staining with untreated (Control) abaxonal membranes of all<br>565 mvelinating SCs. which was particularly intense at the Schwann cell microvilli overlying the 565 myelinating SCs, which was particularly intense at the Schwann cell microvilli overlying the<br>566 node of Ranvier (arrowhead) while (B) very weakly staining these same cells after solvent 566 node of Ranvier (arrowhead) while (**B**) very weakly staining these same cells after solvent<br>567 treatment (Solvent). The control reactions for neuronal (NF200) and myelin (MBP) markers 567 treatment (Solvent). The control reactions for neuronal (NF200) and myelin (MBP) markers<br>568 Fremained unchanged. For this study, the serum-treated fixed cultures were incubated with a 568 remained unchanged. For this study, the serum-treated fixed cultures were incubated with a<br>569 mixture of chloroform. methanol and water at a ratio of 4:8:3 for 1h on ice to remove 569 mixture of chloroform, methanol and water at a ratio of 4:8:3 for 1h on ice to remove<br>570 alvcolipids. The white boxes indicate regions of fluorescence profiling per internode (5 x 20 570 glycolipids. The white boxes indicate regions of fluorescence profiling per internode (5 x 20<br>571 um). Arrows indicate weak paranodal IqG after lipid extraction. (C) The fluorescence 571 µm). Arrows indicate weak paranodal IgG after lipid extraction. (C) The fluorescence<br>572 intensity profiles of the human IgG autoantibodies and myelin basic protein (MBP) 572 intensity profiles of the human IgG autoantibodies and myelin basic protein (MBP)<br>573 immunolabelling across the internodes of control and solvent-treated cultures. Data are immunolabelling across the internodes of control and solvent-treated cultures. Data are

574 presented as mean ( $\pm$  SEM in grey) of two internodes per field of view, 12-14 fields of view<br>575 from two independent experiments. (D) The quantification of lgG:MBP fluorescence ratio.

575 from two independent experiments. (**D**) The quantification of IgG:MBP fluorescence ratio.<br>576 Student's unpaired t-test, p<0.0001, t=5.053, n=24-28 internode profiles per group.

Student's unpaired t-test, p<0.0001, t=5.053, n=24-28 internode profiles per group.

577

<sup>578</sup>**Supplementary Figure 1. Diagram illustrating the patient cohorts and the**  <sup>579</sup>**experimental work flow with their serum samples.** The numbers of patients' serum 580 samples collected in the different categories of ZIKV-GBS (ZIKV patients who developed<br>581 GBS). ZIKV-OND (ZIKV patients who displaved other neurological diseases). ZIKV-CON 581 GBS), ZIKV-OND (ZIKV patients who displayed other neurological diseases), ZIKV-CON<br>582 (ZIKV patients who never developed clinical neurological disease). DENV-CON (DENV 582 (ZIKV patients who never developed clinical neurological disease), DENV-CON (DENV<br>583 patients who never developed clinical neurological disease). ALS (patients with amvotrophic 583 patients who never developed clinical neurological disease), ALS (patients with amyotrophic<br>584 bateral sclerosis, a progressive nervous system disease that affects nerve cells in the brain 584 lateral sclerosis, a progressive nervous system disease that affects nerve cells in the brain<br>585 and spinal cord. causing loss of muscle control). Dysferlin (patients with dysferlinopathy, a 585 and spinal cord, causing loss of muscle control), Dysferlin (patients with dysferlinopathy, a<br>586 muscle diseases that have a slow progression of muscle weakness and atrophy) and 586 muscle diseases that have a slow progression of muscle weakness and atrophy) and<br>587 healthy controls (n. number of patient samples). The patients' serum samples were initially 587 healthy controls (n, number of patient samples). The patients' serum samples were initially<br>588 screened for their autoantibody reactions against different neuronal cell culture types and 588 screened for their autoantibody reactions against different neuronal cell culture types and<br>589 from which the sera from Patients A to D were tested further for their reactions in further 589 from which the sera from Patients A to D were tested further for their reactions in further 590 assavs. assays.

591 Supplementary Figure 2. Simplified heat map showing all screening performed in<br>592 ZIKV-GBS, ZIKV-OND, ZIKV-CON, DENV-CON, ALS, Dysferlin (DYS) and healthy <sup>592</sup>**ZIKV-GBS, ZIKV-OND, ZIKV-CON, DENV-CON, ALS, Dysferlin (DYS) and healthy**  593 **controls (CON) patients.** The reaction scores for each patients' IgG and IgM antibodies<br>594 from each group (ordered alphanumerically) against ZIKV (ELISA), rat dorsal-root ganglia 594 from each group (ordered alphanumerically) against ZIKV (ELISA), rat dorsal-root ganglia<br>595 neurons (DRG) and Schwann cells (SC) are shown by their colour intensity of each square 595 neurons (DRG) and Schwann cells (SC) are shown by their colour intensity of each square<br>596 (0=negative, 1=mild positive, 2=moderate positive, 3=strong positive), while their IgG and 596 (0=negative, 1=mild positive, 2=moderate positive, 3=strong positive), while their IgG and<br>597 IgM antibody reactions with the mvelinating cell co-cultures (CC) were scored as either 597 IgM antibody reactions with the myelinating cell co-cultures (CC) were scored as either<br>598 negative (0) or positive (3). The serum samples that were not tested on a particular assav 598 negative (0) or positive (3). The serum samples that were not tested on a particular assay<br>599 (due to lack of sample or availability) appear blank (ND. not determined). (due to lack of sample or availability) appear blank (ND, not determined).

### <sup>600</sup>**Supplementary Figure 3. Glycolipid microarray results.**

601 Graphical display of the IgG (A) and IgM (B) antibody reaction intensities presented as heat<br>602 maps from blue (negative) to red (strong) for each patients' serum sample from each 602 maps from blue (negative) to red (strong) for each patients' serum sample from each<br>603 clinically classified group (ZIKV-GBS, ZIKV-OND, ZIKV-CON, CON) when reacted against 603 clinically classified group (ZIKV-GBS, ZIKV-OND, ZIKV-CON, CON) when reacted against<br>604 136 different glycolipid targets shown in the 136 rows. No significant differences were 604 136 different glycolipid targets shown in the 136 rows. No significant differences were<br>605 observed between the IgG or IgM antibody reactions against glycolipids and glycolipid 605 observed between the IgG or IgM antibody reactions against glycolipids and glycolipid<br>606 complexes of the ZIKV-GBS patients compared with those of the control group (CON). complexes of the ZIKV-GBS patients compared with those of the control group (CON).

# <sup>607</sup>**Supplementary Figure 4. Patterns of ZIKV serum IgM reactivity against myelinating**  <sup>608</sup>**cell co-cultures.**

609 Immunofluorescent photomicrographs of IgM autoantibodies (A) from a ZIKV-GBS (AIDP)<br>610 patient's sera (patient D. ZN005A) with deposition on individual myelin internodes. (B) from 610 patient's sera (patient D, *ZN005A*) with deposition on individual myelin internodes, (**B**) from<br>611 a male ZIKV-CON patient's serum (patient X. *ZN039B*. 41-45 vears old) with deposition on <sup>611</sup>a male ZIKV-CON patient's serum (patient X, *ZN039B*, 41-45 years old) with deposition on 612 non-myelinating Schwann cell processes, (C) from a female ZIKV-CON patient's serum<br>613 (patient Y. *Z040*. 51-55 vears old) showing strong reactivity against myelin outpouchings and <sup>613</sup>(patient Y, *Z040*, 51-55 years old) showing strong reactivity against myelin outpouchings and <sup>614</sup>**D**) from another female ZIKV-CON patient's serum (patient Z, *Z010*, 81-85 years old) 615 showing weak reactivity against the myelin outpouchings. Counterstaining for NF200 (blue)<br>616 and MBP (red) are also shown. Scale bars. 10 um. The dashed lines illustrate the 616 and MBP (red) are also shown. Scale bars, 10 µm. The dashed lines illustrate the<br>617 transection of mvelin outpouchings and internodes for profile analysis of lgM signal intensity. 617 transection of myelin outpouchings and internodes for profile analysis of IgM signal intensity.<br>618 (E and F) Fluorescent intensity profile plots of patients' IgM autoantibodies (green) and <sup>618</sup>(**E** and **F**) Fluorescent intensity profile plots of patients' IgM autoantibodies (green) and <sup>619</sup>myelin (red) across myelin outpouchings and internodes for the (**E**) strong and (**F**) weak 620 labelling sera. (**G**) The IgM (Alexa 488) autoantibody fluorescence intensities of the ZIKV-621 GBS and ZIKV-CON patients sera compared to the healthy controls against myelin<br>622 outpouchings normalised to internode labelling. One wav ANOVA (all groups): 622 outpouchings normalised to internode labelling. One way ANOVA (all groups):<br>623 F(2.106)=0.7417, p=0.4788). The-healthy-control-serum-samples-which-had-detectable-anti-623  $F(2,106) = 0.7417$ , p=0.4788). The healthy control serum samples which had detectable anti-<br>624  $ZIKV$  antibodies are represented by solid green circles. ZIKV antibodies are represented by solid green circles.

# <sup>625</sup>**Supplementary Figure 5. Axon-binding ZIKV-GBS serum antibodies are exclusively**  <sup>626</sup>**IgG1 subclass, but does not induce complement-mediated injury in neuronal culture.**

627 Immunofluorescent photomicrographs of (A) ZIKV-GBS patient A's serum IgG<br>628 autoantibodies reactions-against-myelinated-sensory-neuron-cell-co-cultures-detected-with 628 autoantibodies reactions against myelinated sensory neuron cell co-cultures detected with<br>629 IgG1, IgG2, IgG3 and IgG4 subclass-specific secondary antibodies and a subsequent 629 IgG1, IgG2, IgG3 and IgG4 subclass-specific secondary antibodies and a subsequent<br>630 fluorescent-labelled tertiary antibody (green) with NF200 labelling used as control counter-630 fluorescent-labelled tertiary antibody (green) with NF200 labelling used as control counter-631 stain (blue). (**B**) Complement-induced injury to sensory neuron cell co-cultures. Incubation<br>632 with ZIKV-GBS patient A's serum at a 1:100 dilution or the anti-ganglioside antibody HA1 at 632 with ZIKV-GBS patient A's serum at a 1:100 dilution or the anti-ganglioside antibody HA1 at 633 50 ug/ml for 1 hr followed by the addition of 20% normal human sera (NHS) containing 633 50 µg/ml for 1 hr followed by the addition of 20% normal human sera (NHS) containing<br>634 complement overnight prior to fixation and immunolabelling. ZIKV-GBS patient A's serum <sup>634</sup>complement overnight prior to fixation and immunolabelling. ZIKV-GBS patient A's serum 635 IgG autoantibody and HA1 binding were detected by fluorescent-labelled anti-human IgG<br>636 and anti-human IgM secondary antibodies, respectively. Note the presence of axonal 636 and anti-human IgM secondary antibodies, respectively. Note the presence of axonal<br>637 swellings (white arrows) and the reduced axon density in the HA1-treated cultures incubated 637 swellings (white arrows) and the reduced axon density in the HA1-treated cultures incubated<br>638 vith 20% NHS. No evidence of axonal injury was observed in the cultures pre-treated with 638 with 20% NHS. No evidence of axonal injury was observed in the cultures pre-treated with 639 the ZIKV-GBS patient A's serum prior to NHS. Scale bars. 20 um. the ZIKV-GBS patient A's serum prior to NHS. Scale bars, 20 µm.

# <sup>640</sup>**Supplementary Figure 6. ZIKA-CON patient B's sera autoantibodies predominantly of**  <sup>641</sup>**the IgG1 subclass.**

642 Immunofluorescent photomicrographs of the ZIKV-CON patient B's serum autoantibodies<br>643 against myelinating SC abaxonal-membranes and detection with either a pan-lgG subclass 643 against myelinating SC abaxonal-membranes and detection with either a pan-IgG subclass<br>644 breactive or IgG1, IgG2, IgG3 and IgG4 subclass-specific secondary antibodies and a 644 reactive or IgG1, IgG2, IgG3 and IgG4 subclass-specific secondary antibodies and a<br>645 subsequent fluorescent-labelled tertiary antibody (green) showing their IgG autoantibodies 645 subsequent fluorescent-labelled tertiary antibody (green) showing their IgG autoantibodies<br>646 predominantly of the IgG1 subclass but also with weaker IgG4 subclass antibodies. 646 predominantly of the IgG1 subclass but also with weaker IgG4 subclass antibodies.<br>647 Counterstaining for NF200 (blue) and MBP (red) are also shown. Scale bars. 20 um. Counterstaining for NF200 (blue) and MBP (red) are also shown. Scale bars, 20  $\mu$ m.

# <sup>648</sup>**Supplementary Figure 7. ZIKV-CON patient B's IgG autoantibody reactions against**  <sup>649</sup>**nerve cell lysates in a western blotting assay.**

650 Different protein concentrations (10, 20 and 40 µg) of myelinated cell co-culture, sensory<br>651 neuron and SC monoculture lysates were subiected to discontinuous acrylamide gel 651 neuron and SC monoculture lysates were subjected to discontinuous acrylamide gel<br>652 electrophoresis and then transferred onto nitrocellulose membranes. Western blotting with <sup>652</sup>electrophoresis and then transferred onto nitrocellulose membranes. Western blotting with 653 ZIKV-CON patient B's serum was followed by sequential steps using peroxidase labelled<br>654 anti-IgG secondary antibodies and ECL substrate and photographic detection. Two protein 654 anti-IgG secondary antibodies and ECL substrate and photographic detection. Two protein<br>655 bands in the mvelinated cell co-cultured Ivsate of relative molecular weights (Mr) of 655 bands in the myelinated cell co-cultured lysate of relative molecular weights (Mr) of<br>656 approximately 62 and 50 kDa were strongly detected by the serum lgG antibodies, but not in 656 approximately 62 and 50 kDa were strongly detected by the serum IgG antibodies, but not in<br>657 the neuronal or Swann cell Ivsates. The Mr standards of 52. 39. 31 and 24 kDa are shown in 657 the neuronal or Swann cell lysates. The Mr standards of 52, 39, 31 and 24 kDa are shown in 658 Iane 1. lane 1.

# <sup>659</sup>**Supplementary Figure 8. Human anti-contactin-1 (CNTN-1) serum IgG binding is not**  <sup>660</sup>**affected by lipid extraction.**

661 Immunofluorescent photomicrographs of the reactions of a diluted human serum which<br>662 contained IqG antibodies against the GPI-linked protein CNTN1 added to myelinated 662 contained IgG antibodies against the GPI-linked protein CNTN1 added to myelinated<br>663 sensory neuron cell co-cultures followed either by (A) immediate (Control) immunolabelling 663 sensory neuron cell co-cultures, followed either by (A) immediate (Control) immunolabelling<br>664 for bound human lgG and neuronal (neurofilament, NF200) proteins or by solvent treatment 664 for bound human IgG and neuronal (neurofilament, NF200) proteins or by solvent treatment<br>665 (Solvent) prior to immunolabelling for bound human IgG and neuronal (neurofilament. 665 (Solvent) prior to immunolabelling for bound human IgG and neuronal (neurofilament,<br>666 NF200) proteins. Scale bars, 20 µm. (B) Quantification of the immunofluorescence labelling 666 NF200) proteins. Scale bars, 20 μm. (**B**) Quantification of the immunofluorescence labelling<br>667 intensities for NF200 and human IgG antibodies per field of view were expressed as a 667 intensities for NF200 and human IgG antibodies per field of view were expressed as a<br>668 percentage of the total area and showed that there was no significant loss of NF200 or 668 percentage of the total area and showed that there was no significant loss of NF200 or<br>669 human lgG-labelled immunofluorescence after before (Control) and after solvent treatment 669 human IgG-labelled immunofluorescence after before (Control) and after solvent treatment<br>670 (Solvent). Identical acquisition and threshold settings were used for each field of view for 670 (Solvent). Identical acquisition and threshold settings were used for each field of view for<br>671 each condition. The Student's unpaired t-tests were used for these comparisons. each condition. The Student's unpaired t-tests were used for these comparisons.

# <sup>672</sup>**Supplementary Figure 9. Effect of neuraminidase treatment of myelinating co-cultures**  <sup>673</sup>**on the reaction of ZIKV-CON patient B's serum IgG autoantibodies**

674 Immunofluorescent photomicrographs of live myelinating co-cultures treated with either (A)<br>675 PBS containing divalent cations for 14 h (D-PBS) or (B) 1U/ml of neuraminidase for 14h 675 PBS containing divalent cations for 14 h (D-PBS) or (**B**) 1U/ml of neuraminidase for 14h<br>676 (Neuraminidase) prior to addition of ZIKV-CON patient B's serum lgG autoantibodies and 676 (Neuraminidase) prior to addition of ZIKV-CON patient B's serum IgG autoantibodies and<br>677 the fluorescent labelled secondary antibodies or control labelling of NF200 and MBP. Scale 677 the fluorescent labelled secondary antibodies or control labelling of NF200 and MBP. Scale<br>678 bars. 10 um. (C) The fluorescence intensity profiles (AU) of human lgG and MBP 678 bars, 10 µm. (C) The fluorescence intensity profiles (AU) of human IgG and MBP<br>679 immunolabelling across internodes of control and solvent-treated cultures. The data are 679 immunolabelling across internodes of control and solvent-treated cultures. The data are<br>680 oresented as the mean values ( $\pm$  SEM in grev) of two internodes per field of view. 6 fields of 680 presented as the mean values ( $\pm$  SEM in grey) of two internodes per field of view, 6 fields of 681 view from two independent experiments. (D) The quantification of IgG:MBP fluorescence 681 view from two independent experiments. (D) The quantification of IgG:MBP fluorescence<br>682 ratios with the Student's unpaired t-test. p=0.3605. t=0.9340. n=12 internode profiles per 682 ratios with the Student's unpaired t-test, p=0.3605, t=0.9340, n=12 internode profiles per 683 group. group.

# <sup>684</sup>**Supplementary Figure 10. Sialic acid cleavage by neuraminidase treatment reduces**  <sup>685</sup>**binding of anti-disialosyl ganglioside but not anti-CNTN1 antibodies.**

Immunofluorescent photomicrographs of the reactions of (**A**) anti-GD2, (**C**) anti-GD3 anti-687 disialosyl ganglioside and (E) anti-CNTN1 GPI-linked protein antibodies (green) against live<br>688 myelinating co-cultures after treatment with either 1U/ml of neuraminidase or D-PBS vehicle myelinating co-cultures after treatment with either 1U/ml of neuraminidase or D-PBS vehicle 689 for 14 h. Counterstaining for NF200 (blue) and MBP (red) are also shown. Scale bars, 20<br>690 µm. The coverage of (B) anti-GD2, (D) anti-GD3 and (F) anti-CNTN1 lgG in the PBS and µm. The coverage of (**B**) anti-GD2, (**D**) anti-GD3 and (**F**) anti-CNTN1 IgG in the PBS and neuraminidase treated cultures expressed as a percentage of axon NF200 area.

## **References**





- 719 with Zika virus infection-associated Guillain-Barre Syndrome in Brazil*. PLoS Negl Trop* 720 Dis 2019;13(9):e0007695. <sup>720</sup>*Dis* 2019;13(9):e0007695.
- 721 12 Medina, MT, England, JD, Lorenzana, I et al., Zika virus associated with sensory<br>722 **http://www.philiperalista control Sci** 2016:369:271-272. <sup>722</sup>polyneuropathy*. J Neurol Sci* 2016;369:271-272.
- 723 13 Oh, Y, Zhang, F, Wang, Y *et al.*, Zika virus directly infects peripheral neurons and<br>724 **induces cell death.** Nat Neurosci 2017:20(9):1209-1212. <sup>724</sup>induces cell death*. Nat Neurosci* 2017;20(9):1209-1212.
- 725 14 Volpi, VG, Pagani, I, Ghezzi, S et al., Zika Virus Replication in Dorsal Root Ganglia<br>726 **Explants from Interferon Receptor1 Knockout Mice Causes Myelin Degeneration**
- <sup>726</sup>Explants from Interferon Receptor1 Knockout Mice Causes Myelin Degeneration*. Sci*  <sup>727</sup>*Rep* 2018;8(1):10166.

728 15 Anaya, JM, Rodriguez, Y, Monsalve, DM et al., A comprehensive analysis and<br>729 **http://www.immunobiology.of autoimmune neurological syndromes during the Zika virus** 729 immunobiology of autoimmune neurological syndromes during the Zika virus outbreak<br>730 in Cucuta. Colombia. J Autoimmun 2017:77:123-138. <sup>730</sup>in Cucuta, Colombia*. J Autoimmun* 2017;77:123-138.

- 731 16 Gallo, V, Egger, M, McCormack, V et al., STrengthening the Reporting of OBservational<br>732 studies in Epidemiology Molecular Epidemiology (STROBE-ME): an extension of the 732 studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the<br>733 STROBE statement. Eur J Clin Invest 2012:42(1):1-16.
- <sup>733</sup>STROBE statement*. Eur J Clin Invest* 2012;42(1):1-16.
- 734 17 Siles, AM, Martinez-Hernandez, E, Araque, J et al., Antibodies against cell adhesion<br>735 molecules and neural structures in paraneoplastic neuropathies. Ann Clin Transl
- <sup>735</sup>molecules and neural structures in paraneoplastic neuropathies*. Ann Clin Transl*  <sup>736</sup>*Neurol* 2018;5(5):559-569.
- 737 18 Clark, AJ, Kaller, MS, Galino, J *et al.*, Co-cultures with stem cell-derived human sensory<br>738 **1988** eurons reveal regulators of peripheral myelination. *Brain* 2017:140(4):898-913. <sup>738</sup>neurons reveal regulators of peripheral myelination*. Brain* 2017;140(4):898-913.
- 739 19 Davies, AJ, Fehmi, J, Senel, M et al., Immunoadsorption and Plasma Exchange in<br>740 Seropositive and Seronegative Immune-Mediated Neuropathies. J Clin Med 740 Seropositive and Seronegative Immune-Mediated Neuropathies. J Clin Med<br>741 2020:9(7):2025. <sup>741</sup>2020;9(7):2025.
- 742 20 Halstead, SK, Kalna, G, Islam, MB et al., Microarray screening of Guillain-Barre<br>743 syndrome sera for antibodies to glycolipid complexes. Neurol Neuroimmunol <sup>743</sup>syndrome sera for antibodies to glycolipid complexes*. Neurol Neuroimmunol*  <sup>744</sup>*Neuroinflamm* 2016;3(6):e284.





- <sup>772</sup>Applications in Target Deconvolution and Off-Target Screening*. SLAS Discov*
- <sup>773</sup>2020;25(2):223-230.
- 774 32 Wang, EY, Dai, Y, Rosen, CE et al., REAP: A platform to identify autoantibodies that<br>775 target the human exoproteome. *bioRxiv* 2021:2021.02.11.430703. target the human exoproteome. bioRxiv 2021:2021.02.11.430703.
- 776 33 Jeong, JS, Jiang, L, Albino, E et al., Rapid identification of monospecific monoclonal<br>777 antibodies using a human proteome microarray. Mol Cell Proteomics 2012;11(6):C <sup>777</sup>antibodies using a human proteome microarray*. Mol Cell Proteomics* 2012;11(6):O111 016253.
- 779 34 Moritz, CP, Tholance, Y, Stoevesandt, O et al., CIDP Antibodies Target Junction Proteins<br>780 and Identify Patient Subaroups: An Autoantigenomic Approach. Neurol Neuroimmunol 780 and Identify Patient Subgroups: An Autoantigenomic Approach*. Neurol Neuroimmunol*<br>781 *Neuroinflamm* **2021;8(2)**. <sup>781</sup>*Neuroinflamm* 2021;8(2).
- 782 35 Lleixà, C, Martín-Aguilar, L, Pascual-Goñi, E *et al.*, Autoantibody screening in Guillain-<sup>783</sup>Barré Syndrome*. Journal of Neuroinflammation* 2021;(in press).













# **Figure 3.**

**0 Like** server **A** Hite<br>  $\vec{r}$ 

**Zika serum only**

**NHS** only

**Vehicle** only

Zikasena Zika

Zika serimoniy

NHS OFFICE

Vehicle only



**TO TB**<br>The security with the

**0**

**Tike setum only** 

**TO**  $\Lambda$ <sup>0</sup>

**Altis of WY** 

**TO**  $\Lambda^{\mathbf{0}}$ 

**Jeticle only** 

**T0 T24**



# **Figure 5**



**NF200 Human IgG MBP Merge**

# **Figure 6.**



**Control**



# **Supplementary Figure 1.**



# **Supplementary Figure 2.**



# **Supplementary Figure 3.**



# **Supplementary Figure 4.**



# **Supplementary Figure 5.**



# **Supplementary Figure 6.**



# **Supplementary Figure 7.**



# **Supplementary Figure 8.**



**Bio-050 (1:200)**

# **Supplementary Figure 9.**



# **Supplementary Figure 10.**

